0IIM
Sign in
Esperion Therapeutics, Inc.
Save
400.97M
Market cap
–
Current P/E
–
Forward P/E
About
Health care
Sector
Medical - Pharmaceuticals
Industry
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program.
Similar securities
Based on sector and market capitalization
Report issue